ArticleActa Cardiologica Sinica2025
Two Sides of the Coin: EPAS-1 as a Potential D-Dimer Alternative in Pulmonary Embolism Evaluation.
Article in Acta Cardiologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Electrocardiographic signs to differentiate between chronic thromboembolic pulmonary hypertension and intermediate-high risk acute pulmonary embolism.Scientific reports · 2026Article
- Prognostic Role of Copeptin, H-FABP, and TTE in Pulmonary Embolism in the Emergency Department.Emergency medicine international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to determine changes in endothelial PAS domain protein-1 (EPAS-1) levels, a biomarker proven to increase with hypoxia, at the time of diagnosis and after treatment in addition to laboratory parameters and scoring systems examined at the time of admission in patients with pulmonary thromboembolism. Methods: The study included 60 pulmonary embolism (PE) patients followed at the Cardiology clinic and 60 control participants with similar demographic characteristics. Laboratory parameters determined at the time of admission were examined. PE risk and severity scores were calculated, and EPAS-1 levels were also measured. To determine the response, EPAS-1 levels were checked 3 days later and compared with the control group. Results: There were no differences between the two groups in terms of demographic characteristics and comorbidities. EPAS-1 levels were higher at the time of diagnosis compared to the control group [(3.6 ± 1.42/1.57 ± 0.45), p < 0.001]. EPAS-1 levels were significantly positively correlated with pulmonary embolism severity index (PESI) severity score and risk score in the patient group. EPAS-1 levels decreased after treatment in the patients, and the tendency to decrease was different according to the types of treatment. In the patients who died, EPAS-1 levels continued to increase despite treatment (p = 0.014). Conclusions: Our study is important in that EPAS-1 levels were correlated with scoring systems and other laboratory parameters used in PE patients, and that it can be used as a predictor in the diagnosis of the disease and play a complementary role in the evaluation of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.